 HOUSTON, July 28, 2021 PRNewswire -- Marker Therapeutics, Inc. Nasdaq:MRKR, a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Companys new cGMP manufacturing facility in Houston, TX, located near the George Bush Intercontinental Airport, is fully operational. The facility will manufacture Markers MultiTAA-specific T cell products for the Companys Phase 2 acute myeloid leukemia AML trial as well as future hematological and solid tumor trials, in addition to producing the potential commercial supply of any approved products. 